Mapi Pharma is a private Israeli clinical-stage pharmaceutical company that is engaged in the development of added-value generic drugs, including complex active pharmaceutical ingredients, formulations, and life cycle management products that target large markets. Mapi Pharma ’s lead product is an extended-release version of Teva Pharmaceuticals Industries Ltd.’s multi-billion dollar drug Copaxone that treats patients with Multiple Sclerosis.